Clinical trial NCT00128284: A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time
Official title: A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastrointestinal Diseases
Stomach Diseases
Gastroparesis
Keywords: gastroparesis
Digestive
Gastrointestinal
Stomach
Motility
Non-Invasive
Capsule
GI
Device
Digestive System Diseases
Lead sponsor: The SmartPill Corporation
Sponsor class: INDUSTRY
First posted: 2005-08-09
Enrollment: 148
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with gastroparesis referred to a tertiary motility center

Brief summary: The purpose of this study is to determine the correlation between gastric residence time of the SmartPill Capsule and the time required for partial emptying of a standard radiolabeled meal as measured by gastric emptying scintigraphy.

Detailed description: Gastric emptying scintigraphy is considered the gold standard for evaluating gastric emptying and is widely available. Accurate characterization of gastric emptying may guide medical and surgical treatment choices. In addition, these techniques may allow for monitoring of therapeutic results for follow-up patient management.

The SmartPill GI Monitoring System offers an alternative non-invasive method for characterizing disorders of the stomach. The system consists of an ingestible capsule that houses sensors for pH, temperature, and pressure, a receiver for receiving and storing signals from the capsule, and software for displaying data on a personal computer. The capsule samples at regular intervals and transmits the sensed pH, pressure, and temperature data to a portable receiver worn by the subject. After test completion, the recorded data is downloaded to a personal computer for subsequent evaluation.

Eligibility criteria: Inclusion Criteria:

Inclusion Criteria For Healthy Subjects:

1. Healthy males and females between ages 18-65 years of age with no gastrointestinal disease as screened by the GI Disease Screening Questionnaire
2. Average bowel movement frequency of at least one bowel movement within 48 hours
3. Subjects with high probability for compliance and completion of the study

Inclusion Criteria For Subjects with Gastroparesis:

1. Abnormal gastric emptying as defined by local standards and documented by nuclear medicine scintigraphy performed within the last two years.
2. Males and females between ages 18-65 years of age.
3. Average bowel movement frequency of at least one bowel movement within 72 hours
4. Subjects with high probability for compliance and completion of the study
5. Upper endoscopy or upper GI within last 3 years showing no evidence of gastric bezoar, stricture, or peptic ulcer.

Exclusion Criteria:

Exclusion Criteria For Healthy Subjects:

1. Prior GI surgery
2. Surgery within the past 3 months
3. Diverticulitis
4. Tobacco use within eight hours prior to capsule ingestion and during the 8 hour monitoring time.
5. Alcohol use within 24 hours prior to capsule ingestion and throughout the entire monitoring period (up to 72 hours).
6. Body mass index (BMI) \> 35
7. Allergies to components of the test meal including eggs, bread, and jam.
8. Female of childbearing age who is not practicing birth control and/or is pregnant or lactating. (Confirm with urine pregnancy test)
9. Cardiovascular, endocrine, renal, or other chronic disease likely to affect motility.

Exclusion Criteria For Subjects with Gastroparesis:

1. History of gastric bezoar
2. Severe dysphagia to solid food and pills
3. Severe vomiting more than 1 time per day
4. Diverticulitis
5. Severe daily abdominal pain requiring medications for relief
6. Severe weight loss, greater than 10 lbs over the preceding 2 months.
7. Uncontrolled diabetes with a hemoglobin A1C greater than 10.
8. Excessively delayed gastric emptying time: more than 90% of a standard egg meal retained after 2 hours.
9. Previous gastro-esophageal surgery including vagotomy, fundoplication, gastric bypass, ulcer surgery.
10. Prior GI surgery except for uncomplicated appendectomy and laparoscopic cholecystectomy
11. Surgery within the past 3 months
12. Tobacco use within eight hours prior to capsule ingestion and during the 8 hour monitoring time.
13. Alcohol use within 24 hours prior to capsule ingestion and throughout the entire monitoring period (up to 72 hours).
14. BMI \> 35
15. Allergies to components of the test meal including eggs, bread, and jam
16. Female of childbearing age who is not practicing birth control and/or is pregnant or lactating. (Confirm with urine pregnancy test)

Primary outcomes:
measure: To demonstrate the correlation between the gastric residence time as determined by SmartPill GI Monitoring System and the gastric emptying time of a radiolabeled meal in both healthy subjects and patients with documented gastroparesis.
timeFrame: 30 minute intervals up to 6 hours
Secondary outcomes:
measure: To demonstrate that the gastric residence time as determined by SmartPill GI Monitoring System can discriminate between healthy human subjects and patients with gastroparesis
timeFrame: Continuous time measure until capsule elimination
measure: To characterize pressure patterns within the antrum and duodenum in healthy subjects and patients with documented gastroparesis
timeFrame: Continuous time measure until capsule elimination
measure: To characterize total GI transit time in healthy subjects
timeFrame: Continuous tume measure until capsule elimination
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: Division of Gastroenterology and Hepatology at KUMC
state: Kansas
city: Louisville
country: United States
facility: University of Louisville Medical Center
state: Kentucky
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan Medical Center
state: Michigan
city: Buffalo
country: United States
facility: VA Medical Center
state: New York
city: Winston-Salem
country: United States
facility: Wake Forest University Baptist Medical Center
state: North Carolina
city: Philadelphia
country: United States
facility: Temple University Medical Center
state: Pennsylvania
Study officials:
affiliation: SmartPill Corporation
name: Jack Semler, PhD
role: STUDY_DIRECTOR
affiliation: Massachusetts General Hospital
name: Braden Kuo, MD
role: PRINCIPAL_INVESTIGATOR
References: